Sanofi’s list prices for Admelog are approximately 15% lower than the originator Humalog’s prices.
Sanofi has launched its short-acting follow-on insulin lispro product, Admelog, referencing Eli Lilly’s Humalog. The rapid-acting human insulin analog is indicated to improve glycemic control in adults and children with diabetes and is available in both vials and in a pen (SoloStar) presentation.
Under Sanofi’s “Insulins VALyou Savings Program,” nonfederally insured patients will be eligible for a savings card that will allow them to purchase the product for a total out-of-pocket cost of $99 for a 10-mL vial or $149 for a box of five 3-mL pens for a period of 12 months. After the year is over, patients can re-register for the program. Sanofi says that the savings program will lower out-of-pocket costs for patients (including the uninsured or patients who are commercially insured under high-deductible plans) who would otherwise have to pay the full list price of $90 per 3-mL pen or $233 per 10-mL vial for Admelog.
Michelle Carnahan, head of North America diabetes and cardiovascular for Sanofi, said that the program will help patients to “…gain access to insulins they need to help manage their disease, at a clear and consistent price, regardless of their pharmacy choice."
Sanofi’s list prices for Admelog are approximately 15% lower than the originator Humalog’s prices, and while these savings are modest in comparison to the historical price increases for insulin lispro—when the brand name Humalog first launched in 1996, it cost just $21 per vial—they do reflect a trend in launch prices for follow-on insulins. Basaglar, Boehringer Ingelheim’s insulin glargine follow-on, launched in 2016 at a 15% discount to the branded Lantus and Toujeo.
Admelog was first tentatively approved by the FDA in September 2017 based on its similarity to the originator insulin lispro, and it was then granted final approval in December 2017 after the conclusion of patent litigation with Eli Lilly concluded. In the United States, follow-on insulin products like Admelog are not regulated as biosimilars; because the FDA treats innovator insulins as drugs, rather than as biologic products, treatments such as Admelog are regulated as follow-ons.
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.